There were 1,517 press releases posted in the last 24 hours and 428,809 in the last 365 days.

Cancer Diagnostics Market is Expected to Surpass USD 185 Billion by 2026, Assesses DelveInsight

The Cancer Diagnostics market size is anticipated to surge owing to the increase in demand for cancer diagnostic products and services. In addition, the establishment of various cancer diagnostic labs, and rising government initiatives to raise awareness regarding early detection and management of cancer among patients, and others are also anticipated to drive the global Cancer Diagnostics market in the upcoming years.

New York, USA, April 04, 2022 (GLOBE NEWSWIRE) -- Cancer Diagnostics Market is Expected to Surpass USD 185 Billion by 2026, Assesses DelveInsight

The Cancer Diagnostics market size is anticipated to surge owing to the increase in demand for cancer diagnostic products and services. In addition, the establishment of various cancer diagnostic labs, and rising government initiatives to raise awareness regarding early detection and management of cancer among patients, and others are also anticipated to drive the global Cancer Diagnostics market in the upcoming years.

DelveInsight's Cancer Diagnostics Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies’ market shares, challenges, market drivers, barriers, and trends, and key Cancer Diagnostics companies in the market.

Key Takeaways from the Cancer Diagnostics Market Report

  • According to DelveInsight analysis, North America is anticipated to dominate the global Cancer Diagnostics market during the forecast period.
  • The leading Cancer Diagnostics companies such as Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ  Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Abbott, General Electric Company, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Guardant Health, Illumina, Inc., QIAGEN, and others are currently dominating the Cancer Diagnostics market.
  • As per DelveInsight estimates, the global Cancer Diagnostics market size is expected to grow at a CAGR of 9.43% during the forecast period (2021-26). 
  • In November 2021, Hologic, Inc. commercially launched its new Genius™ Digital Diagnostics System in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and Cervical Cancer cells in women.
  • In June 2021, NeoGenomics completed its acquisition of Inivata Ltd, a global, commercial-stage liquid biopsy platform company headquartered in Cambridge, England.
  • In August 2020, HTG Molecular Diagnostics, Inc. signed a commercialization and distribution agreement (Master Agreement) with QIAGEN Manchester Limited, a wholly-owned subsidiary of QIAGEN N.V. for companion diagnostic (CDx) assays based on HTG EdgeSeq, HTG’s novel RNA platform.

Explore how the Cancer Diagnostics market size will be growing by 2026? Click to get a snapshot of Cancer Diagnostics Market Growth Analysis

Cancer Diagnostics

Cancer Diagnostic tests are a necessary step toward the proper management of cancer and its progression. There are no single accurate Cancer Diagnostic tests that can be used for cancer diagnosis; the complete evaluation usually requires a thorough history and physical examination along with cancer diagnostics testing. Effective cancer diagnostic testing is used to confirm or eliminate the presence of disease, monitor the disease process, and plan for and evaluate the effectiveness of treatment. Cancer Diagnostic procedures for cancer diagnosis may include a computerized tomography (CT) scan, bone scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, ultrasound, X-ray, among others.

Cancer Diagnostics Market Insights

Among all the other regions, North America has occupied a major share of 42% in the overall Cancer Diagnostics market in 2020 and will continue to dominate during the forecasted period. This domination is due to several factors such as the rise in cancer cases, the presence of key Cancer Diagnostics manufacturers, well-established healthcare infrastructure, and rising awareness regarding cancer and its proper management, among others.

Furthermore, the rise in smoking among adults in the country could be a potential factor for lung cancer diagnostic tests which would, in turn, increase the Cancer Diagnostics market. Moreover, approval of Cancer Diagnostic products to enhance the imaging technology for various cancer detection including breast cancer diagnostics, lung cancer diagnostics, and others will also contribute to the Cancer Diagnostics market. For instance, on November 29, 2021, FDA approved Cytalux (pafolacianine), a targeted fluorescent imaging agent intended to assist surgeons in identifying ovarian cancer lesions. Hence, the interplay of all these factors will drive the Cancer Diagnostics market in the country during the forecasted period.

To know more why North America is leading the market growth in the Cancer Diagnostics market, get a snapshot of the report Global Cancer Diagnostics Market Outlook

Cancer Diagnostics Market Dynamics

The Cancer Diagnostics market is now gaining traction due to an increase in cancer incidence worldwide. Thus, early detection of cancer is required for efficient cancer care, which would lead to a surge in demand for cancer diagnosis, boosting the Cancer Diagnostics market. Furthermore, technological advancements in the production of a variety of cancer diagnostics tools will benefit the market in the approaching years.

However, the negative effects of cancer diagnostic imaging technologies, as well as the high cost of cancer diagnostic products, are anticipated to stymie the global Cancer Diagnostics market.

 Furthermore, the exceptional COVID-19 epidemic harmed the Cancer Diagnostics market. This is owing to the introduction of severe laws by the majority of governments throughout the world to prevent infection spread. Furthermore, as the emphasis has shifted to maintaining healthcare capacity and safeguarding high-risk patients from viral infection, cancer patients have experienced additional barriers to care.

Get a sneak peek at the Cancer Diagnostics market dynamics @ Cancer Diagnostics Market Dynamics Analysis

Scope of the Cancer Diagnostics Market Report

  • Coverage: Global
  • Study Period: 2018-2026
  • Market Segmentation By Type - Reagent & Kits And Instruments, and Services
  • Market Segmentation By Technique - Molecular Diagnostic (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, Immunohistochemistry), Cancer Diagnostic Imaging (Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, Nuclear Medicine Scans), Endoscopy, Biopsy (Standard Biopsy And Liquid Biopsy)
  • Market Segmentation By Cancer Type - Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others
  • Market Segmentation By End-User - Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, and Others
  • Market Segmentation By Geography - North America, Europe, Asia-Pacific, and Rest of World
  • Key Cancer Diagnostics Companies - Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ  Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Abbott, General Electric Company, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Guardant Health, Illumina, Inc., QIAGEN among others
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

DelveInsight Analysis: The Cancer Diagnostics market size is expected to grow at a CAGR of 9.43% during the forecast period from 2021 to 2026 to reach USD 185.08 billion by 2026.

Which MedTech key players in the Cancer Diagnostics market are set to emerge as the trendsetter explore @ Cancer Diagnostics Companies

Table of Contents 

1 Cancer Diagnostics Market Report Introduction
2 Cancer Diagnostics Market Executive summary
3 Regulatory and Patent Analysis
4 Cancer Diagnostics Market Key Factors Analysis
5 Porter’s Five Forces Analysis
6 COVID-19 Impact Analysis on Cancer Diagnostics Market
7 Cancer Diagnostics Market Layout
8 Cancer Diagnostics Global Company Share Analysis – Key 3-5 Companies
9 Cancer Diagnostics Market Company and Product Profiles
10 Project Approach

Learn more about the cancer diagnosis @ Next-generation Cancer Diagnostics Market

Related Reports

Liquid Biopsy in Cancer Diagnostics Market

Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast, 2026 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Liquid Biopsy in Cancer Diagnostics companies such as Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, among others.

Liquid Biopsy for Cancer Diagnostics Pipeline 

Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Analysis, 2022 provides an understanding of the current competition, pipeline products, and changing market dynamics including Liquid Biopsy for Cancer Diagnostics companies such as Guardant Health, Roche, Neo Genomics, Qiagen, among others.

Cancer Therapy Market

Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast, 2026 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Cancer Therapy companies such as GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, among others.

Intratumoral Cancer Therapies Market

Intratumoral Cancer Therapies Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, along with emerging drugs and key Intratumoral Cancer Therapies companies such as  Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, among others.

Non-Small Cell Lung Cancer (NSCLC) Market

Non-Small Cell Lung Cancer Market Insight, Epidemiology, and Market Forecast, 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, along with emerging drugs and key Non-Small Cell Lung Cancer companies such as  Novartis, AbbVie, Janssen Pharmaceuticals, Eli Lilly and Company, among others.

Colorectal Cancer Market

Colorectal Cancer Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, along with emerging drugs and key Colorectal Cancer companies such as  Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, among others.

Other Trending Reports

Chronic Myelocytic Leukemia (CML) Market

Chronic Myelocytic Leukemia (CML) Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Chronic Myelocytic Leukemia (CML) companies such as Novartis Oncology, Servier, Eltrombopag, among others.

Cocaine Use Disorder Market

Cocaine Use Disorder Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Cocaine Use Disorder companies such as Embera NeuroTherapeutics, Novartis, Omeros Corporation, Indivior, among others.

Limbal Stem Cells Deficiency Market

Limbal Stem Cells Deficiency Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Limbal Stem Cells Deficiency companies.

Zollinger-ellison syndrome Market

Zollinger-ellison syndrome Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Zollinger-ellison syndrome companies.

Follicular Lymphoma Market

Follicular Lymphoma Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Follicular Lymphoma companies such as Merck & Co, Genentech, Incyte Corporation, Syndax Pharmaceuticals, among others.

Related Healthcare Blogs

Top Liquid Biopsy Companies Impacting Cancer Diagnostics Market

Upcoming Oncological Drugs

Rare Cancer Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  


Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

https://www.delveinsight.com/medical-devices

Primary Logo